Company Filing History:
Years Active: 2021
Title: Martin Gregory Rowland: Innovator in Pharmaceutical Chemistry
Introduction
Martin Gregory Rowland is a notable inventor based in Sandwich, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical use. His work focuses on creating effective treatments for serious health conditions, including cancer.
Latest Patents
Rowland holds a patent for a crystalline form of lorlatinib free base. This invention relates to a crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base, known as Form 7. The patent also encompasses pharmaceutical compositions that include Form 7 and methods for using this compound in the treatment of abnormal cell growth, such as cancer, in mammals. Rowland's innovative approach aims to enhance the efficacy of cancer treatments.
Career Highlights
Rowland is associated with Pfizer Corporation, a leading global pharmaceutical company. His role at Pfizer allows him to collaborate with other experts in the field and contribute to groundbreaking research and development efforts. His dedication to advancing medical science is evident in his work and the impact it has on patient care.
Collaborations
Rowland has worked alongside talented colleagues, including Klimentina Dimitrova Pencheva and Melissa Jane Birch. These collaborations have fostered a dynamic environment for innovation and have led to significant advancements in pharmaceutical research.
Conclusion
Martin Gregory Rowland is a distinguished inventor whose work in pharmaceutical chemistry has the potential to transform cancer treatment. His innovative contributions, particularly in the development of lorlatinib, highlight the importance of research and collaboration in the fight against serious diseases.